ICMJE DISCLOSURE FORM Date: 2021.02.23 Your Name: Yi Zhao Manuscript Title: Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial Manuscript number (if known): APM-21-443 In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are In the interest of transparency, we ask you to disclose all relationships/activities/interests inserests in the interest of the content of your manuscript. Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>. The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Specifications/Comments (e.g., if payments were made to you or to your institution) Name all entities with whom you have this relationship or indicate none (add rows as Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months any entity (if not indicated in item #1 above). None Royalties or licenses Consulting fees

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10		None	
11		X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	_X_None	
13	Other financial or non- financial interests	<u></u> X_None	
F	No Confilw		following box: - about this study and paper
1	Please place an "X" next to the certify that I have answ form.		o indicate your agreement: have not altered the wording of any of the questions on the
			Yi Zhao

Date: 2021.02.23	
Your Name: Xu Zhang	The second collaboration of th
	cacy and safety of endostatin in combination with chemotherapy in small cell lung cance a
phase 2 single-arm mult	
Manuscript number (if k	nown) APM-21-443

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you gr to your institution)
		Time frame: Since the initi	ai planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	-X, Nor e	
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in Item #1 above),	- X Nore	
3	Royaltim or Ricenses	X None	
4	Consulting fees	Xnone	

3.	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		
ő	Payment for expert testimony	Nune .	
2.	Support for attending meetings and/or travel	X None	
×	Patents planned, Issued or ponding	X None	
9:	Participation on a Data Safety Monitoring Soard or Advisory Soard	X None	
10	Leader ship or fiduciary role in other board, security committee or advocacy group, past or unpaid	XNone	
2,3	Stack or stack options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊀ None	
13	Other financial or non- financial interests	X None	

No Confilict of into	rest about this	study and	paper

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on the form.

Xu Zhong

Date: 2021.02.	23
Your Name: Chenx	ing Jin
Manuscript Title:	Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer:
phase 2 single-arm	multicenter open-label trial
Manuscript numbe	(if known): APM-21-443

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the $\underline{\text{current}}$ $\underline{\text{manuscript only}}$.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
1.25	Marie and the first the said to	Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
-		V	
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
'	meetings and/or travel	- None	
	meetings and/or traver		
8	Patents planned, issued or	√ None	
0	pending	A HOUSE	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or Advisory Board	Manager and the same of the sa	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	V	
11	Stock or stock options	None	
		N	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

No conflict of interest about this study and paper.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Chen Ning

Date: 2021	02.23
Your Name: X	aomin Yu
Manuscript Tit	Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer
phase 2 single-	irm multicenter open-label trial
Manuscript nu	nber (if known): APM-21-443

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entitles with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	× None	
		Time frame: pa	est 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	× None	
3	Royalties or licenses	<u> </u>	
		X None	

	Payment or honoraria for	X None	
	lectures, presentations, speakers burnaus, manuscript writing or educational events		
1	Payment for expert testimony	× Nane	
7	Support for attending meetings and/or travel	-⊀. None	
1	Patents planned, issued or peoding	✓ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10		X None	
11		→ None	
17	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN TW	X None	

No conflict of interest about this study and paper.

Please place an "X" next to the following statement to Indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this

Liaomin Tu

Date:	2021.02.2	3		
Your Nan	ne:_Min Zl	nang		
Manuscri	pt Title:	Efficacy and sa	afety of endostation	n in combination with chemotherapy in small cell lung cancer:
hase 2 s	ingle-arm i	nulticenter ope	en-label trial	
Manuscri	pt number	(if known):	APM-21-443	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the $\underline{\text{current}}$ $\underline{\text{manuscript only}}$.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity(if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	None	

1 200	ment or honoraria for	X None	
lect	ures, presentations, akers bureaus,		
mai	nuscript writing or acational events		
6 Pay	ment for expert		
7 Sup	port for attending etings and/or travel	_X_None	
mee	etings and/or daver		
		× None	
	ents planned, issued or ding		
9 Part	cicipation on a Data	_X_None	
Adv	ety Monitoring Board or isory Board		
10 Lead in or	dership or fiduciary role ther board, society, amittee or advocacy	X None	
grou	up, paid or unpaid	X None	
11 Stoc	k or stock options		
12 Reco	eipt of equipment,		
mat writ	erials, drugs, medical ling, gifts or other		
serv	er financial or non-	XNone	
13 Oth	ncial interests		

Ho conflict of interest about this study and paper.

Please place an "X" next to the following statement to indicate your agreement:

∠ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Min Zhang.

分为被高危者,

Date: 2021.02.23	
Your Name: Yang Cao	
Manuscript Title: Ef	ficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer:
phase 2 single-arm mul	ticenter open-label trial
Manuscript number (if	known):APM-21-443

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	STATE OF THE OWNER, STATE OF	Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	STATE OF THE STATE	Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	X None	
3	lectures, presentations, speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data	<u></u> None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Y None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

No conflict of interest about this study and paper.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Yang Cao

Date: 2021.02.2	23		
Your Name: Ying Li			
Manuscript Title:	Efficacy and s	afety of endostatin in	n combination with chemotherapy in small cell lung cancer: a
phase 2 single-arm	multicenter ope	n-label trial	
Manuscript numbe	r (if known):	APM-21-443	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: pa:	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	X None	
4	Consulting fees	X None	

5	Payment or honoraria for	✓ None		
	lectures, presentations, speakers bureaus, manuscript writing or	- None		
6	Payment for expert testimony	_X_None		
7	Support for attending meetings and/or travel	_X_None		- HARLIS
8	Patents planned, issued or	X None		
9	Participation on a Data Safety Monitoring Board or			
10	Advisory Board	X None		
11	group, paid or unpaid Stock or stock options	X None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	None		
13	Services Other financial or non-financial interests	X_None		
	ease summarize the above c		er.	
	ease place an "X" next to the I certify that I have answe form.			of the questions
			Ying Li	

Date: 2021.02.23		
Your Name: Aman Wang		
Manuscript Title: Efficacy	and safety of endostatin in combination	with chemotherapy in small cell lung cancer:
phase 2 single-arm multicente	r open-label trial	with chemotherapy in small cell lung cancer: a
Manuscript number (if known		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5 Payme	ent or honoraria for	X None						
lectur speak	es, presentations, ers bureaus,	None						
educa	script writing or itional events							
6 Paym testin	ent for expert nony	None						
	ort for attending ings and/or travel	None						
8								
8 Pater pend	nts planned, issued or ing	None						
Safet	cipation on a Data y Monitoring Board or cory Board	None			THE REAL PROPERTY.			
10 Leade in oth	ership or fiduciary role her board, society, nittee or advocacy	None						
	p, paid or unpaid cor stock options	None						
mate	ipt of equipment, erials, drugs, medical ng, gifts or other	None						
servi 13 Othe		None						
Please s	ummarize the above	conflict of interest in	the following bo	ox:				
	o Conflict o	1 Inda- oft	in shir	h. (a.		1		
N	o confua	J menese						
				A.	man.	Wang		
	place an "X" next to the				ng of any o	f the guestic	ons on this	
X 1 co	ertify that I have answ rm.	ered every question	and have not an			***************************************		

Date: 2021.02.23	3				
Your Name: Xiu Sha	n		And the second	and the second	(8)
Manuscript Title:	Efficacy and s	afety of endostatin	in combination wi	th chemotherapy in	small cell lung cancer: a
phase 2 single-arm n				- 100 mm	
Manuscript number	(if known):	APM-21-443			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X None	
4	Consulting fees	None	

1	Payment or honoraria for	⊀ None	
	lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
	Payment for expert testimony	× None	
	Support for attending meetings and/or travel	None	
	Patents planned, issued or pending	None	
	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
)	Leadership or fiduciary role	X_None	The state of the s
	in other board, society, committee or advocacy group, paid or unpaid		A STATE OF THE STA
1	Stock or stock options	None	
i	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other services		
	Other financial or non- financial interests	None	
Ple	ease summarize the above on the		sest ain this paper
		William !	
Pl	ease place an "X" next to th X I certify that I have answ form.	e following statemen ered every question	nt to indicate your agreement: and have not altered the wording of any of the questions on this

The state of

Date: 2021.02		
Your Name: Jia Zh	<u> </u>	
Manuscript Title:_	Efficacy and safety of endostatin in combination with chemotherapy in small cell lung	g cancer: a
phase 2 single-arm	ulticenter open-label trial	
Manuscript number	if known): APM-21-443	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

1		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the inth	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	X None	
	No time limit for this item.		
	No time limit for this item.	Time framel pa	it 36 (months
2		Time frame pas X_None	th 36 months
2	No time limit for this item. Grants or contracts from any entity (if not indicated		R 36 months

_	Payment or honoraria for	X None	
	lectures, presentations,		
_	speakers bureaus,		
	manuscript writing or educational events		
	Payment for expert	X None	
	testimony		
1			
7	Support for attending	_X_None	
1	meetings and/or travel		
-			
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or Advisory Board	200	
10	Leadership or fiduciary role	X None	
0.00	In other board, society,	_A_None	
	committee or advocacy		
11	group, paid or unpaid		
114	Stock or stock options	X None	
12	Receipt of equipment,	_X None	
	moterials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_X_None	
	financial interests		

This manuscript was published without any related support (e.g. relationship/activity/interest)

Please place an "X" next to the following statement to Indicate your agreement:

1 certify that I have answered every question and have not altered the wording of any of the questions on this form.

Jia Zhang

Date: 2021.02.2	3		
The state of the s	STATE OF THE PARTY		uin small cell lung cancer: a
Manuscript Title:	Efficacy and s	fety of endostatin in combination with chem	notherapy in small cell lung cancer
phase 2 single-arm	multicenter ope	n-label trial	
Manuscript number	(if known):	APM-21-443	CONTRACTOR DESCRIPTION OF THE PARTY OF THE P

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

To the last		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
100		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations,	_X_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	X_None	
8	Patents planned, issued or pending	_X_None	
)	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
.0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_None	
1	Stock or stock options	X_None	
	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
	Other financial or non- financial interests	X_None	

No conflict of interest about this study and paper.

Please place an "X" next to the following statement to indicate your agreement:

X | I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Juhong Wang

Date: 2021.02.	23		
Your Name: Liu Yir			
Manuscript Title:	Efficacy and safety of o	endostatin in c	ombination with chemotherapy in small cell lung cancer:
phase 2 single-arm	multicenter open-label t	rial	ombination with themotherapy in small cell lung cancer:
Manuscript number		21-443	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X None	

	Payment or honoraria for	-	
	lectures, presentations, speakers bureaus, manuscript writing or	None	
	Payment for expert testimony	X_None	
	Support for attending meetings and/or travel	-X_None	
	Patents planned, issued or pending	None	
	Participation on a Data Safety Monitoring Board or Advisory Board	None	
0	Leadership or fiduciary role in other board, society, committee or advocacy	None	
1	Stock or stock options	×_None	
2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
3	Other financial or non- financial interests	X_None	
Ple	ease summarize the above o		flot of i'Aeral
Pli	ease place an "X" next to the		indicate your agreement: ave not altered the wording of any of the questions on this
			Liuyin

A STATE OF THE PROPERTY OF THE

Date: 2021.02.2	
Your Name: Xiaoxi	Tan
Manuscript Title:	Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer:
phase 2 single-arm	nulticenter open-label trial
Manuscript numbe	(if known): APM-21-443

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the $\underline{\text{current }}$ $\underline{\text{manuscript only}}$.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entitles with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses		
4	Consulting fees	X_None	

	Payment or honoraria for	X_None						
l ga	lectures, presentations, speakers bureaus, manuscript writing or							
6	Payment for expert testimony	X_None						
7	Support for attending meetings and/or travel	None						
8	Patents planned, issued or pending	None						
9	Participation on a Data Safety Monitoring Board or Advisory Board	✓ None						
10		X None						
11		None						
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None						
13		None						
	Please summarize the above No confd	ict of interest in			est o	n elis	paper	
	Please place an "X" next to th I certify that I have answ form.			not altered	the wording		e questions	on this
			l	Xiad	Xin C	an		

Date: 2021.02	22	ICMJE DISCLOSURE FORM
Your Name: Jiwei		
Manuscript Title:_ phase 2 single-arm	Efficacy and s	afety of endostatin in combination with chemotherapy in small cell lung cancer en-label trial
Manuscript numb		
related to the con parties whose inte to transparency ar	ent of your man rests may be afford d does not nece	eask you to disclose all relationships/activities/interests listed below that are suscript. "Related" means any relation with for-profit or not-for-profit third ected by the content of the manuscript. Disclosure represents a commitment sesarily indicate a bias. If you are in doubt about whether to list a
relationship/activ	ty/interest, it is	preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	X None			
Vi.	lectures, presentations, speakers bureaus, manuscript writing or educational events				
6	Payment for expert testimony	None			
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or pending	√_None			
9	Participation on a Data Safety Monitoring Board or Advisory Board	None			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None			
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		Ellerer	
13	Other financial or non- financial interests	None			
	ease summarize the above	grow of inte	following box:	zzev	
ı	A WE SHAMMER WAS AND A		Ladicate your agreement		
	lease place an "X" next to th				tions on this
	form.				